Zenas BioPharma, Inc.

NasdaqGS:ZBIO Stock Report

Market Cap: US$377.2m

Zenas BioPharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:ZBIO Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
18 Feb 25BuyUS$166,750Leon MoulderIndividual25,000US$6.67
07 Feb 25BuyUS$77,600Tim XiaoIndividual10,000US$7.76
04 Dec 24BuyUS$718,100Leon MoulderIndividual70,000US$10.76
19 Nov 24BuyUS$148,925Leon MoulderIndividual10,000US$15.00
20 Sep 24BuyUS$360,820Tellus BioVentures, LLCCompany20,000US$18.97
16 Sep 24BuyUS$7,480,000Longitude Capital Management Co., LLCCompany440,000US$17.00
16 Sep 24BuyUS$15,000,001Enavate SciencesCompany882,353US$17.00
16 Sep 24BuyUS$37,999,998SR One Capital Management, LPCompany2,235,294US$17.00
16 Sep 24BuyUS$5,100,000Fairmount Funds Management LLCCompany300,000US$17.00
16 Sep 24BuyUS$7,480,000Longitude Capital Management Co., LLCCompany440,000US$17.00
13 Sep 24BuyUS$999,991Hongbo LuIndividual58,823US$17.00

Insider Trading Volume

Insider Buying: ZBIO insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ZBIO?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders366,7360.852%
Private Companies3,761,3598.74%
Public Companies4,513,16110.5%
VC/PE Firms13,969,79232.5%
Institutions20,425,11547.5%

Dilution of Shares: ZBIO only recently listed within the past 12 months

Top Shareholders

Top 25 shareholders own 97.93% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
11.8%
SR One Capital Management, LP
4,911,539US$44.3m0%14.45%
10.1%
Longitude Capital Management Co., LLC
4,229,338US$38.2m69%12.62%
9%
Enavate Sciences
3,761,359US$33.9m0%no data
7.41%
Xencor, Inc.
3,098,380US$28.0m0%no data
6.25%
New Enterprise Associates, Inc.
2,613,948US$23.6m0%1.56%
5.3%
Novo Holdings A/S
2,214,967US$20.0m38.4%0.03%
4.53%
Fairmount Funds Management LLC
1,892,806US$17.1m0%2.34%
4.4%
NVP Associates, LLC
1,838,482US$16.6m0%3.64%
4.26%
FMR LLC
1,781,715US$16.1m-10.9%no data
4%
Tellus BioVentures, LLC
1,672,039US$15.1m0%no data
3.74%
Deerfield Management Company, L.P. Series C
1,562,942US$14.1m0%0.39%
3.38%
Bristol-Myers Squibb Company
1,414,781US$12.8m0%no data
2.83%
Vivo Capital, LLC
1,183,260US$10.7m0%1.08%
2.77%
Federated Hermes, Inc.
1,158,000US$10.5m0%0.03%
2.72%
Wellington Management Group LLP
1,135,289US$10.2m-24.4%no data
2.43%
BlackRock, Inc.
1,014,110US$9.2m0.75%no data
2.34%
The Vanguard Group, Inc.
979,323US$8.8m553%no data
2.1%
Rock Springs Capital Management LP
878,667US$7.9m0%0.41%
1.78%
Perceptive Advisors LLC
744,035US$6.7m-35%0.28%
1.76%
Pivotal BioVenture Partners LLC
736,645US$6.6m13.2%3.84%
1.5%
ArrowMark Colorado Holdings, LLC
627,669US$5.7m109%0.11%
1.22%
T. Rowe Price Group, Inc.
511,220US$4.6m5%no data
0.86%
Morgan Stanley, Investment Banking and Brokerage Investments
357,671US$3.2m615%no data
0.83%
Geode Capital Management, LLC
348,760US$3.1m1,300%no data
0.64%
Leon Moulder
266,155US$2.4m10.4%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/07 05:59
End of Day Share Price 2025/05/07 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zenas BioPharma, Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yigal NochomovitzCitigroup Inc
Yatin SunejaGuggenheim Securities, LLC
Matthew CaufieldH.C. Wainwright & Co.